Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism

Shunsuke Yamada, Masanori Tokumoto, Masatomo Taniguchi, Jiro Toyonaga, Takaichi Suehiro, Rieko Eriguchi, Satoru Fujimi, Hiroaki Ooboshi, Takanari Kitazono, Kazuhiko Tsuruya

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT). The present study was a prospective observational study to determine the effect of cinacalcet treatment on PTG volume and serum biochemical parameters in 60 patients with renal SHPT, already treated with intravenous vitamin D receptor activator (VDRA). Measurement of biochemical parameters and PTG volumes were performed periodically, which were analyzed by stratification into tertiles across the baseline parathyroid hormone (PTH) level or PTG volume. We also determined the factors that can estimate the changes in PTG volume and the achievement of the target PTH range by multivariable analyses. Two years of cinacalcet treatment significantly decreased the serum levels of PTH, calcium, and phosphate, followed by the improvement of achieving the target ranges for these parameters recommended by the Japanese Society for Dialysis Therapy. Cinacalcet decreased the maximal and total PTG volume by about 30%, and also decreased the serum PTH level independent of the baseline serum PTH level and PTG volume. Ten out of 60 patients showed 30% increase in maximal PTG after 2 years. Multivariable analysis showed that patients with nodular PTG at baseline and patients with higher serum calcium and PTH levels at 1 year were likely to exceed the target range of PTH at two years. In conclusion, cinacalcet treatment with intravenous VDRA therapy decreased both PTG volume and serum intact PTH level, irrespective of the pretreatment PTG status and past treatment history.

Original languageEnglish (US)
Pages (from-to)367-377
Number of pages11
JournalTherapeutic Apheresis and Dialysis
Volume19
Issue number4
DOIs
StatePublished - Aug 1 2015

Fingerprint

Secondary Hyperparathyroidism
Parathyroid Glands
Parathyroid Hormone
Renal Dialysis
Serum
Therapeutics
Calcitriol Receptors
Cinacalcet Hydrochloride
Observational Studies
Dialysis
History
Prospective Studies
Calcium

Keywords

  • Cinacalcet
  • Hemodialysis
  • Parathyroid gland
  • Parathyroid hormone
  • Secondary hyperparathyroidism

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism. / Yamada, Shunsuke; Tokumoto, Masanori; Taniguchi, Masatomo; Toyonaga, Jiro; Suehiro, Takaichi; Eriguchi, Rieko; Fujimi, Satoru; Ooboshi, Hiroaki; Kitazono, Takanari; Tsuruya, Kazuhiko.

In: Therapeutic Apheresis and Dialysis, Vol. 19, No. 4, 01.08.2015, p. 367-377.

Research output: Contribution to journalArticle

Yamada, Shunsuke ; Tokumoto, Masanori ; Taniguchi, Masatomo ; Toyonaga, Jiro ; Suehiro, Takaichi ; Eriguchi, Rieko ; Fujimi, Satoru ; Ooboshi, Hiroaki ; Kitazono, Takanari ; Tsuruya, Kazuhiko. / Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism. In: Therapeutic Apheresis and Dialysis. 2015 ; Vol. 19, No. 4. pp. 367-377.
@article{7b9b8b2e38b645c38cf7f6384242fcf2,
title = "Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism",
abstract = "The long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT). The present study was a prospective observational study to determine the effect of cinacalcet treatment on PTG volume and serum biochemical parameters in 60 patients with renal SHPT, already treated with intravenous vitamin D receptor activator (VDRA). Measurement of biochemical parameters and PTG volumes were performed periodically, which were analyzed by stratification into tertiles across the baseline parathyroid hormone (PTH) level or PTG volume. We also determined the factors that can estimate the changes in PTG volume and the achievement of the target PTH range by multivariable analyses. Two years of cinacalcet treatment significantly decreased the serum levels of PTH, calcium, and phosphate, followed by the improvement of achieving the target ranges for these parameters recommended by the Japanese Society for Dialysis Therapy. Cinacalcet decreased the maximal and total PTG volume by about 30{\%}, and also decreased the serum PTH level independent of the baseline serum PTH level and PTG volume. Ten out of 60 patients showed 30{\%} increase in maximal PTG after 2 years. Multivariable analysis showed that patients with nodular PTG at baseline and patients with higher serum calcium and PTH levels at 1 year were likely to exceed the target range of PTH at two years. In conclusion, cinacalcet treatment with intravenous VDRA therapy decreased both PTG volume and serum intact PTH level, irrespective of the pretreatment PTG status and past treatment history.",
keywords = "Cinacalcet, Hemodialysis, Parathyroid gland, Parathyroid hormone, Secondary hyperparathyroidism",
author = "Shunsuke Yamada and Masanori Tokumoto and Masatomo Taniguchi and Jiro Toyonaga and Takaichi Suehiro and Rieko Eriguchi and Satoru Fujimi and Hiroaki Ooboshi and Takanari Kitazono and Kazuhiko Tsuruya",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/1744-9987.12292",
language = "English (US)",
volume = "19",
pages = "367--377",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism

AU - Yamada, Shunsuke

AU - Tokumoto, Masanori

AU - Taniguchi, Masatomo

AU - Toyonaga, Jiro

AU - Suehiro, Takaichi

AU - Eriguchi, Rieko

AU - Fujimi, Satoru

AU - Ooboshi, Hiroaki

AU - Kitazono, Takanari

AU - Tsuruya, Kazuhiko

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT). The present study was a prospective observational study to determine the effect of cinacalcet treatment on PTG volume and serum biochemical parameters in 60 patients with renal SHPT, already treated with intravenous vitamin D receptor activator (VDRA). Measurement of biochemical parameters and PTG volumes were performed periodically, which were analyzed by stratification into tertiles across the baseline parathyroid hormone (PTH) level or PTG volume. We also determined the factors that can estimate the changes in PTG volume and the achievement of the target PTH range by multivariable analyses. Two years of cinacalcet treatment significantly decreased the serum levels of PTH, calcium, and phosphate, followed by the improvement of achieving the target ranges for these parameters recommended by the Japanese Society for Dialysis Therapy. Cinacalcet decreased the maximal and total PTG volume by about 30%, and also decreased the serum PTH level independent of the baseline serum PTH level and PTG volume. Ten out of 60 patients showed 30% increase in maximal PTG after 2 years. Multivariable analysis showed that patients with nodular PTG at baseline and patients with higher serum calcium and PTH levels at 1 year were likely to exceed the target range of PTH at two years. In conclusion, cinacalcet treatment with intravenous VDRA therapy decreased both PTG volume and serum intact PTH level, irrespective of the pretreatment PTG status and past treatment history.

AB - The long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT). The present study was a prospective observational study to determine the effect of cinacalcet treatment on PTG volume and serum biochemical parameters in 60 patients with renal SHPT, already treated with intravenous vitamin D receptor activator (VDRA). Measurement of biochemical parameters and PTG volumes were performed periodically, which were analyzed by stratification into tertiles across the baseline parathyroid hormone (PTH) level or PTG volume. We also determined the factors that can estimate the changes in PTG volume and the achievement of the target PTH range by multivariable analyses. Two years of cinacalcet treatment significantly decreased the serum levels of PTH, calcium, and phosphate, followed by the improvement of achieving the target ranges for these parameters recommended by the Japanese Society for Dialysis Therapy. Cinacalcet decreased the maximal and total PTG volume by about 30%, and also decreased the serum PTH level independent of the baseline serum PTH level and PTG volume. Ten out of 60 patients showed 30% increase in maximal PTG after 2 years. Multivariable analysis showed that patients with nodular PTG at baseline and patients with higher serum calcium and PTH levels at 1 year were likely to exceed the target range of PTH at two years. In conclusion, cinacalcet treatment with intravenous VDRA therapy decreased both PTG volume and serum intact PTH level, irrespective of the pretreatment PTG status and past treatment history.

KW - Cinacalcet

KW - Hemodialysis

KW - Parathyroid gland

KW - Parathyroid hormone

KW - Secondary hyperparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=84941943039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941943039&partnerID=8YFLogxK

U2 - 10.1111/1744-9987.12292

DO - 10.1111/1744-9987.12292

M3 - Article

C2 - 25851690

AN - SCOPUS:84941943039

VL - 19

SP - 367

EP - 377

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 4

ER -